therapeutic window

The therapeutic index (TI) is calculated as TD50/ED50 (the dose causing toxicity in 50% of the population divided by the dose producing the desired effect in 50% of the population), though clinically it's often approximated using TD50/ED50 or the ratio of toxic dose to effective dose in a population. A larger TI indicates a safer drug with more room for dosing error, whereas drugs with a narrow therapeutic index (NTI drugs) require therapeutic drug monitoring (TDM) because small changes in dose or blood concentration can lead to toxicity or therapeutic failure.

Classic examples of narrow therapeutic index drugs tested on boards include: warfarin (monitored via INR), digoxin (narrow window, toxicity causes arrhythmias, GI symptoms, visual disturbances - yellow-green halos), lithium (monitored for nephrogenic diabetes insipidus, tremor, and toxicity signs), phenytoin (zero-order kinetics complicate dosing), theophylline, aminoglycosides (nephrotoxicity/ototoxicity), cyclosporine/tacrolimus (immunosuppressants), and vancomycin.

Factors affecting the therapeutic window include patient-specific pharmacokinetic variables (renal/hepatic function, age, genetic polymorphisms in metabolizing enzymes like CYP450), drug interactions that alter clearance, and the drug's inherent pharmacodynamic profile. Clinically, this concept is crucial for dosing decisions, especially in patients with organ dysfunction, polypharmacy, or extremes of age. Drugs with wide therapeutic indices (e.g., penicillins) allow more flexible dosing without frequent monitoring, while NTI drugs necessitate serum drug level monitoring to balance efficacy and safety.